Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Brain
Published in: Molecular Brain 1/2013

Open Access 01-12-2013 | Review

Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms

Authors: Khanh vinh quốc Lương, Lan Thi Hoàng Nguyễn

Published in: Molecular Brain | Issue 1/2013

Login to get access

Abstract

Evidence suggests that there are aberrations in the vitamin D-endocrine system in subjects with amyotrophic lateral sclerosis (ALS). Here, we review the relationship between vitamin D and ALS. Vitamin D deficiency was reported in patients with ALS. Dietary vitamin D3 supplementation improves functional capacity in the G93A transgenic mouse model of ALS. Genetic studies have provided an opportunity to identify the proteins that link vitamin D to ALS pathology, including major histocompatibility complex (MHC) class II molecules, toll-like receptors, poly(ADP-ribose) polymerase-1, heme oxygenase-1, and calcium-binding proteins, as well as the reduced form of nicotinamide adenine dinucleotide phosphate. Vitamin D also exerts its effect on ALS through cell-signaling mechanisms, including glutamate, matrix metalloproteinases, mitogen-activated protein kinase pathways, the Wnt/β-catenin signaling pathway, prostaglandins, reactive oxygen species, and nitric oxide synthase.
In conclusion, vitamin D may have a role in ALS. Further investigation of vitamin D in ALS patients is needed.
Appendix
Available only for authorised users
Literature
1.
Sato Y, Honda Y, Asoh T, Kikuyama M, Oizumi K: Hypovitaminosis D and decreased bone mineral density in amyotrophic lateral sclerosis. Eur Neurol. 1997, 37: 225-229. 10.1159/000117447.PubMed
2.
Yanagihara R, Garruto RM, Gajdusek DC, Tomita A, Uchikawa T: Calcium and vitamin D metabolism in Guamanian Chamorros with amyotrophic lateral sclerosis and parkinsonism-dementia. Ann Neurol. 1984, 15: 42-48. 10.1002/ana.410150108.PubMed
3.
Karam C, Scelsa SN: Can vitamin D delay the progression of ALS?. Med Hypotheses. 2011, 76: 643-645. 10.1016/j.mehy.2011.01.021.PubMed
4.
Shen L: Further support for vitamin D supplement in delaying the progression of ALS. Med Hypotheses. 2011, 77: 698-PubMed
5.
Ezura Y, Nakajima T, Kajita M, Ishida R, Inoue S: Association of molecular variants, haplotypes, and linkage disequilibrium within the human vitamin D-binding protein (DBP) gene with postmenopausal bone mineral density. J Bone Miner Res. 2003, 18: 1642-1649. 10.1359/jbmr.2003.18.9.1642.PubMed
6.
Speeckaert M, Huang G, Delanghe JR, Taes YE: Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta. 2006, 372: 33-42. 10.1016/j.cca.2006.03.011.PubMed
7.
White P, Cooke N: The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol Metab. 2000, 11: 320-327. 10.1016/S1043-2760(00)00317-9.PubMed
8.
Palma AS, De Carvalho M, Grammel N, Pinto S, Barata N: Proteomic analysis of plasma from Portuguese patients with familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008, 9: 339-349. 10.1080/17482960801934239.PubMed
9.
Kamel F, Umbach DM, Hu H, Munsat TL, Shefner JM: Lead exposure as a risk factor for amyotrophic lateral sclerosis. Neurodegener Dis. 2005, 2: 195-201. 10.1159/000089625.PubMed
10.
Lee SS, Lee BK, Lee GS, Stewart WF, Simon D: Associations of lead biomarkers and delta-aminolevulinic acid dehydratase and vitamin D receptor genotypes with hematopoietic outcomes in Korean lead workers. Scand J Work Environ Health. 2001, 27: 402-411. 10.5271/sjweh.633.PubMed
11.
Schwartz BS, Lee BK, Lee GS, Stewart WF, Simon D: Associations of blood lead, dimercaptosuccinic acid-chelatable lead, and tibia lead with polymorphisms in the vitamin D receptor and δ-aminolevulinic acid dehydratase genes. Environ Health Perspect. 2000, 108: 949-954.PubMedCentralPubMed
12.
Chabas JF, Alluin O, Rao G, Garcia S, Lavaut MN: Vitamin D2 potentiates axon regeneration. J Neurotrauma. 2008, 25: 1247-1256. 10.1089/neu.2008.0593.PubMed
13.
Gianforcaro A, Hamadeh MJ: Dietary vitamin D3 supplementation at 10× the adequate intake improves functional capacity in the G93A transgenic mouse model of ALS, a pilot study. CNS Neurosci Ther. 2012, 18: 547-557. 10.1111/j.1755-5949.2012.00316.x.PubMed
14.
Kawamata T, Akiyama H, Yamada T, McGeer PL: Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992, 140: 691-707.PubMedCentralPubMed
15.
Troost D, Das PK, van den Oord JJ, Louwerse ES: Immunohistological alterations in muscle of patients with amyotrophic lateral sclerosis: mononuclear cell phenotypes and expression of MHC products. Clin Neuropathol. 1992, 11: 115-120.PubMed
16.
Oliveira AS, Isozaki E, Younger D, Gabbai AA, Hays AP: Expression of HLA-DR in peripheral nerve of amyotrophic lateral sclerosis. Arq Neuropsiquiatr. 1994, 52: 493-500. 10.1590/S0004-282X1994000400007.PubMed
17.
Penna G, Adorini L: 1 Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol. 2000, 164: 2405-2411.PubMed
18.
Penna G, Adorini L: Inhibition of costimulatory pathways for T-cell activation by 1,25-dihydroxyvitamin D3. Transplant Proc. 2001, 33: 2083-2084. 10.1016/S0041-1345(01)01957-1.PubMed
19.
Ferreira GB, Overbergh L, Verstuyf A, Mathieu C: 1α,25-Dihydroxyvitamin D3 and its analogs as modulators of human dendritic cells: A comparison dose-titration study. J Steroid Biochem Mol Biol. 2012, 10.1016/j.jsbmb.2012.10.009. [Epub ahead of print]
20.
Zügel U, Steinmeyer A, May E, Lehmann M, Asadullah K: Immunomodulation by a novel, dissociated Vitamin D analogue. Exp Dermatol. 2009, 18: 619-27. 10.1111/j.1600-0625.2009.00845.x.PubMed
21.
Scherberich J, Kellermeyer M, Ried C, Hartinger A: 1-alpha-calcidol modulates major human monocyte antigens and toll-like receptors TRL2 and TRL4 in vitro. Eur J Med Res. 2005, 10: 179-82.PubMed
22.
Bartels LE, Hvas CL, Agnholt J, Dahlerup JF, Agger R: Human dendritic cell antigen presentation and chemotaxis are inhibited by intrinsic 25-hydroxy vitamin D activation. Int Immunopharmacol. 2010, 10: 922-8. 10.1016/j.intimp.2010.05.003.PubMed
23.
Gowing G, Philips T, Van Wijmeersch B, Audet JN, Dewil M: Ablation of proliferating microglia does not affect motor neuron degeneration in amyotrophic lateral sclerosis caused by mutant superoxide dismutase. J Neurosci. 2008, 28: 10234-44. 10.1523/JNEUROSCI.3494-08.2008.PubMed
24.
Nguyen MD, D’Aigle T, Gowing G, Julien J-P, Rivest S: Exacerbation of Motor Neuron Disease by Chronic Stimulation of Innate Immunity in a Mouse Model of Amyotrophic Lateral Sclerosis. J Neurosci. 2004, 24: 1340-9. 10.1523/JNEUROSCI.4786-03.2004.PubMed
25.
Letiembre M, Liu Y, Walter S, Hao W, Pfander T: Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging. 2009, 30: 759-68. 10.1016/j.neurobiolaging.2007.08.018.PubMed
26.
Liu Y, Hao W, Dawson A, Liu S, Fassbender K: Expression of amyotrophic lateral sclerosis-linked SOD1 mutant increases the neurotoxic potential of microglia via TLR2. J Biol Chem. 2009, 284: 3691-9.PubMed
27.
Zhang R, Hadlock KG, Do H, Yu S, Honrada R: Gene expression profiling in peripheral blood mononuclear cells from patients with sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol. 2011, 230: 114-23. 10.1016/j.jneuroim.2010.08.012.PubMedCentralPubMed
28.
Casula M, Iyer AM, Spliet WG, Anink JJ, Steentjes K: Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 2011, 179: 233-43.PubMed
29.
Goos M, Zech WD, Jaiswal MK, Balakrishnan S, Ebert S: Expression of a Cu Zn superoxide dismutase typical for familial amyotrophic lateral sclerosis increases the vulnerability of neuroblastoma cells to infectious injury. BMC Infect Dis. 2007, 7: 131-10.1186/1471-2334-7-131.PubMedCentralPubMed
30.
Sadeghi K, Wessner B, Laggner U, Ploder M, Tamandl D: Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol. 2006, 36: 361-70. 10.1002/eji.200425995.PubMed
31.
Dickie L, Church L, Coulthard L, Mathews R, Emery P, McDermott M: Vitamin D3 downregulates intracellular toll-like receptor 9 expression and toll-like receptor 9-induced IL-6 production in human monocytes. Rheumatol. 2010, 48: 1466-71.
32.
Liu PT, Stenger S, Li H, Wenzel L, Tan BH: Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006, 311: 1770-3. 10.1126/science.1123933.PubMed
33.
Krishnakumar R, Kraus WL: The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell. 2010, 39: 8-24. 10.1016/j.molcel.2010.06.017.PubMedCentralPubMed
34.
Kim SH, Engelhardt JI, Henkel JS, Siklós L, Soós J: Widespread increased expression of the DNA repair enzyme PARP in brain in ALS. Neurology. 2004, 62: 319-22. 10.1212/01.WNL.0000103291.04985.DC.PubMed
35.
Kim SH, Henkel JS, Beers DR, Sengun IS, Simpson EP: PARP expression is increased in astrocytes but decreased in motor neurons in the spinal cord of sporadic ALS patients. J Neuropathol Exp Neurol. 2003, 62: 88-103.PubMed
36.
Chung YH, Joo KM, Lee YJ, Shin DH, Cha CI: Reactive astrocytes express PARP in the central nervous system of SODG93A transgenic mice. Brain Res. 2004, 1003: 199-204. 10.1016/j.brainres.2004.01.010.PubMed
37.
Eliasson MJ, Sampei K, Mandir AS, Hurn PD, Traystman RJ: Poly(ADP-ribose) polymerase gene disruption renders mice resistant to cerebral ischemia. Nat Med. 1997, 3: 1089-95. 10.1038/nm1097-1089.PubMed
38.
Mandir AS, Przedborski S, Jackson-Lewis V, Wang ZQ, Simbulan-Rosenthal CM: Poly(ADP-ribose) polymerase activation mediates 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism. Proc Natl Acad Sci U S A. 1999, 96: 5774-9. 10.1073/pnas.96.10.5774.PubMedCentralPubMed
39.
Kauppinen TM, Suh SW, Higashi Y, Berman AE, Escartin C: Poly(ADP-ribose)polymerase-1 modulates microglial responses to amyloid β. J Neuroinflammation. 2011, 8: 152-10.1186/1742-2094-8-152.PubMedCentralPubMed
40.
Hivert B, Cerruti C, Camu W: Hydrogen peroxide-induced motoneuron apoptosis is prevented by poly ADP ribosyl synthetase inhibitors. Neuroreport. 1998, 9: 1835-8. 10.1097/00001756-199806010-00031.PubMed
41.
Andreassen OA, Dedeoglu A, Friedlich A, Ferrante KL, Hughes D: Effects of an inhibitor of poly(ADP-ribose) polymerase, desmethylselegiline, trientine, and lipoic acid in transgenic ALS mice. Exp Neurol. 2001, 168: 419-24. 10.1006/exnr.2001.7633.PubMed
42.
Moore M, Piazza A, Nolan Y, Lynch MA: Treatment with dexamethasone and vitamin D3 attenuates neuroinflammatory age-related changes in rat hippocampus. Synapse. 2007, 61: 851-61. 10.1002/syn.20433.PubMed
43.
Bhatia M, Kirkland JB, Mecking-Gill KA: Modulation of poly(ADP-ribose) polymerase during neurophilic and monocytic differentiation of promyelocytic (NB4) and myelocytic (HL-60) leakaemia cells. Biochem J. 1995, 308: 131-7.PubMedCentralPubMed
44.
Mabley JG, Wallace R, Pacher P, Murphy K, Szab C: Inhibition of poly(adenosine diphosphate-ribose) polymerase by the active form of vitamin D. Int J Mol Med. 2007, 9 (6): 947-952.
45.
Takahashi T, Morita K, Akagi R, Sassa S: Protective role of heme oxygenase-1 in renal ischemia. Antioxid Redox Signal. 2004, 6: 867-77.PubMed
46.
Song W, Su H, Song S, Paudel HK, Schipper HM: Over-expression of heme oxygenase-1 promotes oxidative mitochondrial damage in rat astroglia. J Cell Physiol. 2006, 206: 655-63. 10.1002/jcp.20509.PubMed
47.
Guo Y, Wang Q, Zhang K, An T, Shi P: HO-1 induction in motor cortex and intestinal dysfunction in TDP-43 A315T transgenic mice. Brain Res. 2012, 1460: 88-95.PubMed
48.
Guo Y, Duan W, Li Z, Huang J, Yin Y: Decreased GLT-1 and increased SOD1 and HO-1 expression in astrocytes contribute to lumbar spinal cord vulnerability of SOD1-G93A transgenic mice. FEBS Lett. 2010, 584: 1615-22. 10.1016/j.febslet.2010.03.025.PubMed
49.
Sato K, Morimoto N, Kurata T, Mimoto T, Miyazaki K: Impaired response of hypoxic sensor protein HIF-1α and its downstream proteins in the spinal motor neurons of ALS model mice. Brain Res. 2012, 1473: 55-62.PubMed
50.
Shih PK, Chen YC, Huang YC, Chang YT, Chen JX, Cheng CM: Pretreatment of vitamin D3 ameliorates lung and muscle injury induced by reperfusion of bilateral femoral vessels in a rat model. J Surg Res. 2011, 171: 323-8. 10.1016/j.jss.2010.03.008.PubMed
51.
Oermann E, Bidmon H-J, Witte O-W, Zilles K: Effects of 1α,25-didroxyvitamin D3 on the expression of HO-1 and GFAP in glial cells of the photothrombotically lesioned cerebral cortex. J Chem Neuroanat. 2004, 28: 225-38. 10.1016/j.jchemneu.2004.07.003.PubMed
52.
Kadowaki K, McGowan E, Mock G, Chandler S, Emson PC: Distribution of calcium binding protein mRNAs in rat cerebellar cortex. Neurosci Lett. 1993, 153: 80-4. 10.1016/0304-3940(93)90082-V.PubMed
53.
Bernard-Marissal N, Moumen A, Sunyach C, Pellegrino C, Dudley K: Reduced calreticulin levels link endoplasmic reticulum stress and Fas-triggered cell death in motoneurons vulnerable to ALS. J Neurosci. 2012, 32: 4901-12. 10.1523/JNEUROSCI.5431-11.2012.PubMed
54.
Elliott JL, Snider WD: Parvalbumin is a marker of ALS-resistant motor neurons. Neuroreport. 1995, 6: 449-52. 10.1097/00001756-199502000-00011.PubMed
55.
Alexianu ME, Ho BK, Mohamed AH, La Bella V, Smith RG, Appel SH: The role of calcium-binding proteins in selective motoneuron vulnerability in amyotrophic lateral sclerosis. Ann Neurol. 1994, 36: 846-58. 10.1002/ana.410360608.PubMed
56.
Sasaki S, Warita H, Komori T, Murakami T, Abe K, Iwata M: Parvalbumin and calbindin D-28 k immunoreactivity in transgenic mice with a G93A mutant SOD1 gene. Brain Res. 2006, 1083: 196-203. 10.1016/j.brainres.2006.01.129.PubMed
57.
Chung YH, Joo KM, Nam RH, Cho MH, Kim DJ: Decreased expression of calretinin in the cerebral cortex and hippocampus of SOD1G93A transgenic mice. Brain Res. 2005, 1035: 105-9. 10.1016/j.brainres.2004.12.022.PubMed
58.
Dekkers J, Bayley P, Dick JR, Schwaller B, Berchtold MW, Greensmith L: Over-expression of parvalbumin in transgenic mice rescues motoneurons from injury-induced cell death. Neuroscience. 2004, 123: 459-66. 10.1016/j.neuroscience.2003.07.013.PubMed
59.
Beers DR, Ho BK, Siklós L, Alexianu ME, Mosier DR: Parvalbumin overexpression alters immune-mediated increases in intracellular calcium, and delays disease onset in a transgenic model of familial amyotrophic lateral sclerosis. J Neurochem. 2001, 79: 499-509.PubMed
60.
Ho BK, Alexianu ME, Colom LV, Mohamed AH, Serrano F, Appel SH: Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity. Proc Natl Acad Sci U S A. 1996, 93: 6796-801. 10.1073/pnas.93.13.6796.PubMedCentralPubMed
61.
Das A, Wallace G, Reiter RJ, Varma AK, Ray SK, Banik NL: Overexpression of melatonin membrane receptors increases calcium-binding proteins and protects VSC4.1 motoneurons from glutamate toxicity through multiple mechanisms. J Pineal Res. 2012, 10.1111/j.1600-079X.2012.01022.x. [Epub ahead of print]
62.
Leathers VL, Linse S, Forsén S, Norman AW: Calbindin-D28K, a 1 α,25-dihydroxyvitamin D3-induced calcium-binding protein, binds five or six Ca2+ ions with high affinity. J Biol Chem. 1990, 265: 9838-41.PubMed
63.
Halhali A, Figueras AG, Díaz L, Avila E, Barrera D: Effects of calcitriol on calbindins gene expression and lipid peroxidation in human placenta. J Steroid Biochem Mol Biol. 2010, 121: 448-51. 10.1016/j.jsbmb.2010.03.008.PubMed
64.
de Viragh PA, Haglid KG, Celio MR: Parvalbumin increases in the caudate putamen of rats with vitamin D hypervitaminosis. Proc Natl Acad Sci U S A. 1989, 86: 3887-90. 10.1073/pnas.86.10.3887.PubMedCentralPubMed
65.
Alexianu ME, Robbins E, Carswell S, Appel SH: 1α, 25 dihydroxyvitamin D3-dependent up-regulation of calcium-binding proteins in motoneuron cells. J Neurosci Res. 1998, 51: 58-66. 10.1002/(SICI)1097-4547(19980101)51:1<58::AID-JNR6>3.0.CO;2-K.PubMed
66.
Jaronen M, Vehviläinen P, Malm T, Keksa-Goldsteine V, Pollari E: Protein disulfide isomerase in ALS mouse glia links protein misfolding with NADPH oxidase-catalyzed superoxide production. Hum Mol Genet. 2013, 22: 646-55. 10.1093/hmg/dds472.PubMed
67.
Harraz MM, Marden JJ, Zhou W, Zhang Y, Williams A: SOD1 mutations disrupt redox-sensitive Rac regulation of NADPH oxidase in a familial ALS model. J Clin Invest. 2008, 118: 659-70.PubMedCentralPubMed
68.
Marden JJ, Harraz MM, Williams AJ, Nelson K, Luo M: Redox modifier genes in amyotrophic lateral sclerosis in mice. J Clin Invest. 2007, 117: 2913-9. 10.1172/JCI31265.PubMedCentralPubMed
69.
Boucherie C, Schäfer S, Lavand’homme P, Maloteaux JM, Hermans E: Chimerization of astroglial population in the lumbar spinal cord after mesenchymal stem cell transplantation prolongs survival in a rat model of amyotrophic lateral sclerosis. J Neurosci Res. 2009, 87: 2034-46. 10.1002/jnr.22038.PubMed
70.
Hashizume K, Suzuki S, Ichikawa K, Takeda T, Kobayashi M: Effect of active vitamin D3 on the levels of NADPH-dependent cytosolic 3,5,3′-triiodo-L-thyronine-binding protein. Biochem Biophys Res Commun. 1991, 177: 388-94. 10.1016/0006-291X(91)91995-O.PubMed
71.
Stio M, Lunghi B, Iantomasi T, Vincenzini MT, Treves C: Effect of vitamin D deficiency and 1,25-dihydroxyvitamin D3 on rat heart metabolism. J Mol Cell Cardiol. 1994, 26: 1421-8. 10.1006/jmcc.1994.1161.PubMed
72.
Bachelet M, Bader C, Merlot AM, Laborde K, Snarska J, Ulmann A: Cellular utilization of cytosolic NADPH in kidney and liver cells from rats fed a normal or a vitamin D-deficient diet. Cell Biochem Funct. 1983, 1: 25-9. 10.1002/cbf.290010105.PubMed
73.
Luong K, Nguyen L: The Beneficial Role of Vitamin D in Alzheimer’s Disease. Am J Alzheimers Dis Other Demen. 2011 Nov, 26 (7): 511-20. 10.1177/1533317511429321.
74.
Luong K, Nguyen L: Role of vitamin d in Parkinson’s disease. ISRN Neurol. 2012, 2012: 134289-PubMedCentral
75.
Niessen HG, Debska-Vielhaber G, Sander K, Angenstein F, Ludolph AC: Metabolic progression markers of neurodegeneration in the transgenic G93A-SOD1 mouse model of amyotrophic lateral sclerosis. Eur J Neurosci. 2007, 25: 1669-77. 10.1111/j.1460-9568.2007.05415.x.PubMed
76.
Choi J-K, Küstermann E, Dedeoglu A, Jenkins BG: Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur J Neurosci. 2009, 30: 2143-50. 10.1111/j.1460-9568.2009.07015.x.PubMedCentralPubMed
77.
Andreadou E, Kapaki E, Kokotis P, Paraskevas GP, Katsaros N: Plasma glutamate and glycine levels in patients with amyotrophic lateral sclerosis. In Vivo. 2008, 22: 137-41.PubMed
78.
Plaitakis A, Constantakakis E: Altered metabolism of excitatory amino acids, N-acetyl-aspartate and N-acetyl-aspartyl-glutamate in amyotrophic lateral sclerosis. Brain Res Bull. 1993, 30: 381-6. 10.1016/0361-9230(93)90269-H.PubMed
79.
Ferrarese C, Sala G, Riva R, Begni B, Zoia C: Decreased platelet glutamate uptake in patients with amyotrophic lateral sclerosis. Neurology. 2001, 56: 270-2. 10.1212/WNL.56.2.270.PubMed
80.
Rothstein JD, Martin LJ, Kuncl RW: Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N Engl J Med. 1992, 326: 1464-8. 10.1056/NEJM199205283262204.PubMed
81.
Bos IW, Hoogland G, Meine Jansen CF, Willigen G, Spierenburg HA: Increased glutamine synthetase but normal EAAT2 expression in platelets of ALS patients. Neurochem Int. 2006, 48: 306-11. 10.1016/j.neuint.2005.09.009.PubMed
82.
Deng Y, Xu Z, Xu B, Tian Y, Xin X: The protective effect of riluzole on manganese caused disruption of glutamate-glutamine cycle in rats. Brain Res. 2009, 1289: 106-17.PubMed
83.
Atif F, Sayeed I, Ishrat T, Stein DG: Progesterone with vitamin D affords better neuroprotection against excitotoxicity in cultured cortical neurons than progesterone alone. Mol Med. 2009, 15: 328-36.PubMedCentralPubMed
84.
Ibi M, Sawada H, Nakanishi M, Kume T, Katsuki H: Protective effects of 1 alpha,25-(OH)2D3 against the neurotoxicity of glutamate and reactive oxygen species in mesencephalic culture. Neuropharmacology. 2001, 40: 761-71. 10.1016/S0028-3908(01)00009-0.PubMed
85.
Kajta M, Makarewicz D, Ziemińska E, Jantas D, Domin H: Neuroprotection by co-treatment and post-treating with calcitriol following the ischemic and excitotoxic insult in vivo and in vitro. Neurochem Int. 2009, 55: 265-74. 10.1016/j.neuint.2009.03.010.PubMed
86.
Taniura H, Ito M, Sanada N, Kuramoto N, Ohno Y: Chronic vitamin D3 treatment protects against neurotoxicity by glutamate in association with upregulation of vitamin D receptor mRNA expression in cultured rat cortical neurons. J Neurosci Res. 2006, 83: 1179-89. 10.1002/jnr.20824.PubMed
87.
Lim GP, Backstrom JR, Cullen MJ, Miller CA, Atkinson RD, Tökés ZA: Matrix metalloproteinases in the neocortex and spinal cord of amyotrophic lateral sclerosis patients. J Neurochem. 1996, 67: 251-9.PubMed
88.
Beuche W, Yushchenko M, Mäder M, Maliszewska M, Felgenhauer K, Weber F: Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport. 2000, 11: 3419-22. 10.1097/00001756-200011090-00003.PubMed
89.
Niebroj-Dobosz I, Janik P, Sokołowska B, Kwiecinski H: Matrix metalloproteinases and their tissue inhibitors in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2010, 17: 226-31. 10.1111/j.1468-1331.2009.02775.x.PubMed
90.
Fang L, Huber-Abel F, Teuchert M, Hendrich C, Dorst J: Linking neuron and skin: matrix metalloproteinases in amyotrophic lateral sclerosis (ALS). J Neurol Sci. 2009, 285: 62-6. 10.1016/j.jns.2009.05.025.PubMed
91.
Fang L, Teuchert M, Huber-Abel F, Schattauer D, Hendrich C: MMP-2 and MMP-9 are elevated in spinal cord and skin in a mouse model of ALS. J Neurol Sci. 2010, 294: 51-6. 10.1016/j.jns.2010.04.005.PubMed
92.
Demestre M, Parkin-Smith G, Petzold A, Pullen AH: The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol. 2005, 159: 146-54. 10.1016/j.jneuroim.2004.09.015.PubMed
93.
Kiaei M, Kipiani K, Calingasan NY, Wille E, Chen J: Matrix metalloproteinase-9 regulates TNF-alpha and FasL expression in neuronal, glial cells and its absence extends life in a transgenic mouse model of amyotrophic lateral sclerosis. Exp Neurol. 2007, 205: 74-81. 10.1016/j.expneurol.2007.01.036.PubMed
94.
Lorenzl S, Narr S, Angele B, Krell HW, Gregorio J: The matrix metalloproteinases inhibitor Ro 28–2653 [correction of Ro 26–2853] extends survival in transgenic ALS mice. Exp Neurol. 2006, 200: 166-71. 10.1016/j.expneurol.2006.01.026.PubMed
95.
Sundar I, Hwang J, Wu S, Sun J, Rahman I: Deletion of vitamin D receptor leads to premature emphysema/COPD by increased matrix metalloproteinase and lymphoid aggregates formation. Biochem Biophys Res Commun. 2011, 406: 127-33. 10.1016/j.bbrc.2011.02.011.PubMedCentralPubMed
96.
Timms P, Mannan N, Hitman G: Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders?. Q J Med. 2002, 95: 787-96. 10.1093/qjmed/95.12.787.
97.
Dean DD, Schwartz Z, Schmitz J, Muniz OE, Lu Y: Vitamin D regulation of metalloproteinase activity in matrix vesicles. Connect Tissue Res. 1996, 35: 331-6. 10.3109/03008209609029208.PubMed
98.
Lacraz S, Dayer J, Nicod L, Welgus H: 1,25-dihydroxyvitamin D3 dissociates production of interstitial collagenase and 92-kDa gelatinase in human mononuclear phagocytes. J Biol Chem. 1994, 269: 6485-90.PubMed
99.
Kim EK, Choi EJ: Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta. 1802, 2010: 396-405.
100.
Bendotti C, Atzori C, Piva R, Tortarolo M, Strong MJ: Activated p38MAPK is a novel component of the intracellular inclusions found in human amyotrophic lateral sclerosis and mutant SOD1 transgenic mice. J Neuropathol Exp Neurol. 2004, 63: 113-9.PubMed
101.
Holasek SS, Wengenack TM, Kandimalla KK, Montano C, Gregor DM: Activation of the stress-activated MAP kinase, p38, but not JNK in cortical motor neurons during early presymptomatic stages of amyotrophic lateral sclerosis in transgenic mice. Brain Res. 2005, 1045: 185-98. 10.1016/j.brainres.2005.03.037.PubMed
102.
Tortarolo M, Veglianese P, Calvaresi N, Botturi A, Rossi C: Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol Cell Neurosci. 2003, 23: 180-92. 10.1016/S1044-7431(03)00022-8.PubMed
103.
Veglianese P, Lo Coco D, Bao Cutrona M, Magnoni R, Pennacchini D: Activation of the p38MAPK cascade is associated with upregulation of TNF alpha receptors in the spinal motor neurons of mouse models of familial ALS. Mol Cell Neurosci. 2006, 31: 218-31. 10.1016/j.mcn.2005.09.009.PubMed
104.
Dewil M, dela Cruz VF, Van Den Bosch L, Robberecht W: Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. Neurobiol Dis. 2007, 26: 332-41. 10.1016/j.nbd.2006.12.023.PubMed
105.
Sun C, Qi R, Wang L, Yan J, Wang Y: p38 MAPK regulates calcium signal-mediated lipid accumulation through changing VDR expression in primary preadipocytes of mice. Mol Biol Rep. 2012, 39: 3179-84. 10.1007/s11033-011-1084-8.PubMed
106.
Ravid A, Rubinstein E, Gamady A, Rotem C, Liberman UA, Koren R: Vitamin D inhibits the activation of stress-activated protein kinases by physiological and environmental stresses in keratinocytes. J Endocrinol. 2002, 173: 525-32. 10.1677/joe.0.1730525.PubMed
107.
Zhang Y, Leung DY, Richers BN, Liu Y, Remigio LK: Vitamin D inhibits monocyte/macrophage proinflammatory cytokine production by targeting MAPK phosphatase-1. J Immunol. 2012, 188: 2127-35. 10.4049/jimmunol.1102412.PubMedCentralPubMed
108.
Tetich M, Kutner A, Leskiewicz M, Budziszewska B, Lasoń W: Neuroprotective effects of (24R)-1,24-dihydroxycholecalciferol in human neuroblastoma SH-SY5Y cell line. J Steroid Biochem Mol Biol. 2004, 89–90: 365-70.PubMed
109.
Parr BA, Shea MJ, Vassileva G, McMahon AP: Mouse Wnt genes exhibit discrete domains of expression in the early embryonic CNS and limb buds. Development. 1993, 119: 247-61.PubMed
110.
Lorca RA, Chacón M, Barría MI, Inestrosa NC, Huidobro-Toro JP: Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry. 2003, 8: 195-208. 10.1038/sj.mp.4001208.
111.
Inestrosa NC, Toledo EM: The role of Wnt signaling in neuronal dysfunction in Alzheimer’s Disease. Mol Neurodegener. 2008, 3: 9-10.1186/1750-1326-3-9.PubMedCentralPubMed
112.
Inestrosa NC, Arenas E: Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010, 11: 77-86. 10.1038/nrn2755.PubMed
113.
Chen Y, Guan Y, Zhang Z, Liu H, Wang S: Wnt signaling pathway is involved in the pathogenesis of amyotrophic lateral sclerosis in adult transgenic mice. Neurol Res. 2012, 34: 390-9.PubMed
114.
Chen Y, Guan Y, Liu H, Wu X, Yu L: Activation of the Wnt/β-catenin signaling pathway is associated with glial proliferation in the adult spinal cord of ALS transgenic mice. Biochem Biophys Res Commun. 2012, 420: 397-403. 10.1016/j.bbrc.2012.03.006.PubMed
115.
Pálmer HG, González-Sancho JM, Espada J, Berciano MT, Puig I: Vitamin D3 promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J Cell Biol. 2001, 154: 369-87. 10.1083/jcb.200102028.PubMedCentralPubMed
116.
Byers S, Shah S: Vitamin D and the regulation of Wnt/beta-catenin signaling and innate immunity in colorectal cancer. Nutr Rev. 2007, 65: S118-20. 10.1301/nr.2007.aug.S118-S120.PubMed
117.
Iłzecka J: Prostaglandin E2 is increased in amyotrophic lateral sclerosis patients. Acta Neurol Scand. 2003, 108: 125-9. 10.1034/j.1600-0404.2003.00102.x.PubMed
118.
Almer G, Teismann P, Stevic Z, Halaschek-Wiener J, Deecke L: Increased levels of the pro-inflammatory prostaglandin PGE2 in CSF from ALS patients. Neurology. 2002, 58: 1277-9. 10.1212/WNL.58.8.1277.PubMed
119.
Maihöfner C, Probst-Cousin S, Bergmann M, Neuhuber W, Neundörfer B, Heuss D: Expression and localization of cyclooxygenase-1 and −2 in human sporadic amyotrophic lateral sclerosis. Eur J Neurosci. 2003, 18: 1527-34. 10.1046/j.1460-9568.2003.02879.x.PubMed
120.
Liang X, Wang Q, Shi J, Lokteva L, Breyer RM: The prostaglandin E2 EP2 receptor accelerates disease progression and inflammation in a model of amyotrophic lateral sclerosis. Ann Neurol. 2008, 64: 304-14. 10.1002/ana.21437.PubMedCentralPubMed
121.
Miyagishi H, Kosuge Y, Ishige K, Ito Y: Expression of microsomal prostaglandin E synthase-1 in the spinal cord in a transgenic mouse model of amyotrophic lateral sclerosis. J Pharmacol Sci. 2012, 118: 225-36. 10.1254/jphs.11221FP.PubMed
122.
Shin JH, Lee YA, Lee JK, Lee YB, Cho W: Concurrent blockade of free radical and microsomal prostaglandin E synthase-1-mediated PGE2 production improves safety and efficacy in a mouse model of amyotrophic lateral sclerosis. J Neurochem. 2012, 122: 952-61. 10.1111/j.1471-4159.2012.07771.x.PubMed
123.
Yasojima K, Tourtellotte WW, McGeer EG, McGeer PL: Marked increase in cyclooxygenase-2 in ALS spinal cord: implications for therapy. Neurology. 2001, 57: 952-6.PubMed
124.
Yokota O, Terada S, Ishizu H, Ishihara T, Nakashima H: Increased expression of neuronal cyclooxygenase-2 in the hippocampus in amyotrophic lateral sclerosis both with and without dementia. Acta Neuropathol. 2004, 107: 399-405. 10.1007/s00401-004-0826-2.PubMed
125.
Okuno T, Nakatsuji Y, Kumanogoh A, Koguchi K, Moriya M: Induction of cyclooxygenase-2 in reactive glial cells by the CD40 pathway: relevance to amyotrophic lateral sclerosis. J Neurochem. 2004, 91: 404-12. 10.1111/j.1471-4159.2004.02727.x.PubMed
126.
Drachman DB, Frank K, Dykes-Hoberg M, Teismann P, Almer G: Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann Neurol. 2002, 52: 771-8. 10.1002/ana.10374.PubMed
127.
Kiaei M, Kipiani K, Petri S, Choi DK, Chen J: Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem. 2005, 93: 403-11. 10.1111/j.1471-4159.2005.03024.x.PubMed
128.
Carbone LD, Tylavsky FA, Cauley JA, Harris TB, Lang TF: Association between bone mineral density and the use of nonsteroidal anti-inflammatory drugs and aspirin: impact of cyclooxygenase selectivity. J Bone Miner Res. 2003, 18: 1795-802. 10.1359/jbmr.2003.18.10.1795.PubMed
129.
Moreno J, Krishnan AV, Swami S, Nonn L, Peehl DM, Feldman D: Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Res. 2005, 65: 7917-25.PubMed
130.
Keeting PE, Li CH, Whipkey DL, Thweatt R, Xu J: 1,25-Dihydroxyvitamin D3 pretreatment limits prostaglandin biosynthesis by cytokine-stimulated adult human osteoblast-like cells. J Cell Biochem. 1998, 68: 237-46. 10.1002/(SICI)1097-4644(19980201)68:2<237::AID-JCB10>3.0.CO;2-C.PubMed
131.
Aparna R, Subhashini J, Roy KR, Reddy GS, Robinson M: Selective inhibition of cyclooxygenase-2 (COX-2) by 1 α,25-dihydroxy- 16-ene-23-yne-vitamin D3, a less calcemic vitamin D analog. J Cell Biochem. 2008, 104: 1832-42. 10.1002/jcb.21749.PubMed
132.
Pichaud F, Roux S, Frendo JL, Delage-Mourroux R, Maclouf J: 1,25-dihydroxyvitamin D3 induces NAD+-dependent 15-hydroxyprostaglandin dehydrogenase in human neonatal monocytes. Blood. 1997, 89: 2105-12.PubMed
133.
Velásquez-Forero F, García P, Triffitt JT, Llach F: Prostaglandin E1 increases in vivo and in vitro calcitriol biosynthesis in rabbits. Prostaglandins Leukot Essent Fatty Acids. 2006, 75: 107-15. 10.1016/j.plefa.2006.03.011.PubMed
134.
Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J: Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler. 2008, 9: 177-83. 10.1080/17482960801933942.PubMedCentralPubMed
135.
Said Ahmed M, Hung WY, Zu JS, Hockberger P, Siddique T: Increased reactive oxygen species in familial amyotrophic lateral sclerosis with mutations in SOD1. J Neurol Sci. 2000, 176: 88-94. 10.1016/S0022-510X(00)00317-8.PubMed
136.
Liu D, Wen J, Liu J, Li L: The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999, 13: 2318-28.PubMed
137.
Uchino M, Ando Y, Tanaka Y, Nakamura T, Uyama E: Decrease in Cu/Zn- and Mn-superoxide dismutase activities in brain and spinal cord of patients with amyotrophic lateral sclerosis. J Neurol Sci. 1994, 127: 61-7. 10.1016/0022-510X(94)90136-8.PubMed
138.
Rizzardini M, Mangolini A, Lupi M, Ubezio P, Bendotti C, Cantoni L: Low levels of ALS-linked Cu/Zn superoxide dismutase increase the production of reactive oxygen species and cause mitochondrial damage and death in motor neuron-like cells. J Neurol Sci. 2005, 232: 95-103. 10.1016/j.jns.2005.02.004.PubMed
139.
Flanagan SW, Anderson RD, Ross MA, Oberley LW: Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem. 2002, 81: 170-7. 10.1046/j.1471-4159.2002.00812.x.PubMed
140.
Zimmerman MC, Oberley LW, Flanagan SW: Mutant SOD1-induced neuronal toxicity is mediated by increased mitochondrial superoxide levels. J Neurochem. 2007, 102: 609-18. 10.1111/j.1471-4159.2007.04502.x.PubMed
141.
Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C: Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett. 1999, 260: 204-6. 10.1016/S0304-3940(98)00986-0.PubMed
142.
Chi L, Ke Y, Luo C, Gozal D, Liu R: Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience. 2007, 144: 991-1003. 10.1016/j.neuroscience.2006.09.064.PubMedCentralPubMed
143.
Gluck WL, Weinberg JB: 1 alpha,25 Dihydroxyvitamin D3 and mononuclear phagocytes: enhancement of mouse macrophage and human monocyte hydrogen peroxide production without alteration of tumor cytolysis. J Leukoc Biol. 1987, 42: 498-503.PubMed
144.
Cohen MS, Mesler DE, Snipes RG, Gray TK: 1,25-Dihydroxyvitamin D3 activates secretion of hydrogen peroxide by human monocytes. J Immunol. 1986, 136: 1049-53.PubMed
145.
Levy R, Malech HL: Effect of 1,25-dihydroxyvitamin D3, lipopolysaccharide, or lipoteichoic acid on the expression of NADPH oxidase components in cultured human monocytes. J Immunol. 1991, 147: 3066-71.PubMed
146.
Bao BY, Ting HJ, Hsu JW, Lee YF: Protective role of 1α, 25-dihydroxyvitamin D3 against oxidative stress in nonmalignant human prostate epithelial cells. Int J Cancer. 2008, 122: 2699-2706. 10.1002/ijc.23460.PubMed
147.
Somjen D, Katzburg S, Grafi-Cohen M, Knoll E, Sharon O, Posner GH: Vitamin D metabolites and analogs induce lipoxygenase mRNA expression and activity as well as reactive oxygen species (ROS) production in human bone cell line. J Steroid Biochem Mol Biol. 2011, 123: 85-89. 10.1016/j.jsbmb.2010.11.010.PubMed
148.
Garcion E, Sindji L, Leblondel G, Brachet P, Darcy F: 1,25-dihydroxyvitamin D3 regulates the synthesis of γ-glutamyl transpeptidase and glutathione levels in rat primary astrocytes. J Neurochem. 1999, 73: 859-66.PubMed
149.
Cookson MR, Menzies FM, Manning P, Eggett CJ, Figlewicz DA: Cu/Zn superoxide dismutase (SOD1) mutations associated with familial amyotrophic lateral sclerosis (ALS) affect cellular free radical release in the presence of oxidative stress. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002, 3: 75-85.PubMed
150.
Almer G, Vukosavic S, Romero N, Przedborski S: Inducible nitric oxide synthase up-regulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem. 1999, 72: 2415-25.PubMed
151.
Chang JM, Kuo MC, Kuo HT, Hwang SJ, Tsai JC: 1-α,25-Dihydroxyvitamin D3 regulates inducible nitric oxide synthase messenger RNA expression and nitric oxide release in macrophage-like RAW264.7 cells. J Lab Clin Med. 2004, 143: 14-22. 10.1016/j.lab.2003.08.002.PubMed
152.
Garcion E, Nataf S, Berod A, Darcy F, Brachet P: 1,25-Dihydroxyvitamin D3 inhibits the expression of inducible nitric oxide synthase in rat central nervous system during experimental allergic encephalomyelitis. Brain Res Mol Brain Res. 1997, 45: 255-67. 10.1016/S0169-328X(96)00260-4.PubMed
153.
Equils O, Naiki Y, Shapiro AM, Michelsen K, Lu D: 1,25-Dihydroxyvitamin D3 inhibits lipopolysaccharide-induced immune activation in human endothelial cells. Clin Exp Immunol. 2006, 143: 58-64. 10.1111/j.1365-2249.2005.02961.x.PubMedCentralPubMed
154.
Tare M, Emmett SJ, Coleman HA, Skordilis C, Eyles DW: Vitamin D insufficiency is associated with impaired vascular endothelial and smooth muscle function and hypertension in young rats. J Physiol. 2011, 589: 4777-86. 10.1113/jphysiol.2011.214726.PubMedCentralPubMed
Metadata
Title
Roles of vitamin D in amyotrophic lateral sclerosis: possible genetic and cellular signaling mechanisms
Authors
Khanh vinh quốc Lương
Lan Thi Hoàng Nguyễn
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Molecular Brain / Issue 1/2013
Electronic ISSN: 1756-6606
DOI
https://doi.org/10.1186/1756-6606-6-16

Other articles of this Issue 1/2013

Molecular Brain 1/2013 Go to the issue

Research

NMDA receptor subunits have different roles in NMDA-induced neurotoxicity in the retina

Research

Delay-dependent impairment of spatial working memory with inhibition of NR2B-containing NMDA receptors in hippocampal CA1 region of rats

Research

The neuropeptide Y Y1 receptor knockdown modulates activator protein 1-involved feeding behavior in amphetamine-treated rats

Research

Role of metabotropic glutamate receptor 5 signaling and homer in oxygen glucose deprivation-mediated astrocyte apoptosis

Review

Transcriptional regulation and its misregulation in Alzheimer’s disease

Research

Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo